Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

(2020) Zunyou Wu et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.

(2020) Gordon Cook et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

(2020) Chenguang Shen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

(2020) Evangelos Terpos et al.   LEUKEMIA

Compassionate Use of Remdesivir for Patients with Severe Covid-19

(2020) Jonathan Grein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating the burden of SARS-CoV-2 in France

(2020) Henrik Salje et al.   SCIENCE

COVID-19 in Immunocompromised Hosts: What We Know So Far

(2020) Monica Fung et al.   CLINICAL INFECTIOUS DISEASES

Outcome of COVID‐19 in multiple myeloma patients in relation to treatment

(2020) Katharina Helene Susek et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

(2020) Bo Wang et al.   Journal of Hematology & Oncology

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

(2020) Joaquín Martínez-López et al.   Blood Cancer Journal

Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients

(2020) Abi Vijenthira et al.   BLOOD

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

(2020) Ajai Chari et al.   BLOOD

Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies

(2018) Min Chen et al.   ANNALS OF HEMATOLOGY

Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials

(2018) Jennifer L. J. Heaney et al.   LEUKEMIA

Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study

(2018) Rasmus Sørrig et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population

(2017) Rasmus Sørrig et al.   PLoS One

Multiple myeloma epidemiology and survival: A unique malignancy

(2016) Dickran Kazandjian   SEMINARS IN ONCOLOGY

Changing treatment paradigms for patients with plasma cell myeloma: Impact upon immune determinants of infection

(2014) Benjamin W. Teh et al.   BLOOD REVIEWS

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

(2014) C. Blimark et al.   HAEMATOLOGICA

The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection

(2009) M. Basler et al.   JOURNAL OF IMMUNOLOGY